FDA Safety Official Testifies COX-2 Inhibitors Have Cardiovascular Risks Similar to Smoking at Advisory Committee Meeting

COX-2 inhibitors increase risk for cardiovascular events at about the same rate as cigarette smoking, hypertension and diabetes, FDA Office of Drug Safety Officer David Graham told an agency advisory committee on Thursday, the Washington Post reports (Kaufman, Washington Post, 2/18).

Source: MedicalNewsToday